Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis
Open Access
- 24 January 2005
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 35 (6), 567-575
- https://doi.org/10.1038/sj.bmt.1704826
Abstract
Treatment of patients with AL amyloidosis with high-dose melphalan and autologous peripheral blood stem cells (PBSC) produces hematologic remissions in approximately 40% of evaluable patients, accompanied by improvements in organ disease and quality of life. These patients, who frequently have amyloid deposits in bone marrow blood vessels and interstitium and impaired function of kidneys, liver, spleen, and heart, represent an unusual population for stem cell transplantation, with unique problems. To identify factors influencing engraftment rates after chemotherapy and autologous granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC reinfusion, we studied a group of 225 patients. The median time to neutrophil engraftment was 10 days (range, 8-17 days). In a multivariate analysis, the factors positively affecting the rate of neutrophil engraftment were CD34+ stem cell dose, female gender, and minimal prior alkylator therapy. The median time to platelet engraftment was 13 days (range, 7-52 days). Factors positively affecting platelet engraftment, in addition to CD34+ cell dose, included preserved renal function and the absence of neutropenic fever. The conditioning dose of intravenous melphalan was not found to be an independent predictive factor for hematopoietic recovery. Thus, in this patient population, organ function and host and hematopoietic factors influence engraftment after PBSC rescue.Keywords
This publication has 28 references indexed in Scilit:
- Bone Marrow Core Biopsy Specimens in AL (Primary) AmyloidosisAmerican Journal of Clinical Pathology, 2003
- Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignanciesBone Marrow Transplantation, 2002
- Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status reportBone Marrow Transplantation, 2000
- Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantationBone Marrow Transplantation, 1999
- Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantationBone Marrow Transplantation, 1997
- Daily Measurements of Blood CD34+ Cells After Stem Cell Mobilization Predict Stem Cell Yield and Posttransplant Hematopoietic RecoveryJournal of Hematotherapy, 1997
- Autologous Transplantation of Blood Stern Cells Mobilized with Filgrastim Alone in 93 Patients with Malignancies: The Number of CD34+ Cells Reinfused Is the Only Factor Predicting Both Granulocyte and Platelet RecoveryJournal of Hematotherapy, 1996
- Peripheral Blood Progenitor Cell Transplantation: A Replacement for Marrow Auto‐ or AllograftsThe International Journal of Cell Cloning, 1996
- Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda).JCI Insight, 1982
- Amyloid Fibril Proteins: Proof of Homology with Immunoglobulin Light Chains by Sequence AnalysesScience, 1971